These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 445304)

  • 21. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer.
    Paternoster D; Maggino T; Valente S; Paternoster A; Pengo V; Marchesoni D
    Clin Exp Obstet Gynecol; 1981; 8(2):64-5. PubMed ID: 7199979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for gynecologic cancer. Vulvar, vaginal, endometrial, and ovarian neoplasms.
    Hall KL; Dewar MA; Perchalski J
    Prim Care; 1992 Sep; 19(3):607-20. PubMed ID: 1410066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ovarian carcinoma-associated antigen isolated from peritoneal effusions in clinical diagnosis].
    Qian HN
    Zhonghua Fu Chan Ke Za Zhi; 1983 Oct; 18(4):242-6. PubMed ID: 6426896
    [No Abstract]   [Full Text] [Related]  

  • 25. Carcinoembryonic antigen in ovarian cancer: correlation of concentrations in tumour tissue, cyst fluid, ascitic fluid and peripheral blood.
    Khoo SK; Hill R; Daunter B; Mackay EV
    Aust N Z J Obstet Gynaecol; 1982 May; 22(2):65-70. PubMed ID: 6958253
    [No Abstract]   [Full Text] [Related]  

  • 26. [Placental protein 12 (PP 12) in cyst and peritoneal fluids and serum samples of patients with ovarian cysts and cystic ovarian tumors].
    Strache RR; Göcze PM; Szábo DG; Büttner HH; Briese V; Kunze M; Csaba IF; Röpcke G
    Zentralbl Gynakol; 1989; 111(11):749-54. PubMed ID: 2781888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tumor markers in epithelial ovarian cancer].
    Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G
    Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for ovarian cancer.
    Goswamy RK; Campbell S; Whitehead MI
    Clin Obstet Gynaecol; 1983 Dec; 10(3):621-43. PubMed ID: 6653033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of the Stockholm screening study on ovarian cancer.
    Einhorn N; Bast R; Knapp R; Nilsson B; Zurawski V; Sjövall K
    Gynecol Oncol; 2000 Dec; 79(3):466-70. PubMed ID: 11104621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CA 125 in peritoneal washings and fluid: correlation with plasma CA 125 and peritoneal cytology.
    Schwartz PE; Chambers SK; Chambers JT; Tilton K; Foemmel R
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):339-42. PubMed ID: 2915859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
    Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
    Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian cancer: immunologic diagnosis and therapy.
    Barber HR; Dorsett B
    Contrib Gynecol Obstet; 1985; 14():176-84. PubMed ID: 3905251
    [No Abstract]   [Full Text] [Related]  

  • 33. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer].
    Lahousen M
    Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour markers in ovarian cancer.
    van Nagell JR
    Clin Obstet Gynaecol; 1983 Aug; 10(2):197-212. PubMed ID: 6193919
    [No Abstract]   [Full Text] [Related]  

  • 35. Measurement of crosslinked fibrin derivatives in plasma and ascitic fluid with monoclonal antibodies against D dimer using EIA and latex test.
    Hafter R; Schröck R; von Hugo R; Graeff H
    Scand J Clin Lab Invest Suppl; 1985; 178():137-44. PubMed ID: 3867114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor antigens in ovarian malignancy.
    Rubin SC; Lewis JL
    Clin Obstet Gynecol; 1986 Sep; 29(3):693-704. PubMed ID: 2428553
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation and comparison of hemocoagulation parameters both in serum and in ascites from patients with gynecologic malignancies.
    Varcaccio-Garofalo G; Selvaggi L; Capozza G; Orlando E; Ferreri R; Restaino A
    Eur J Gynaecol Oncol; 1982; 3(2):113-4. PubMed ID: 7166171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer.
    Paternoster D; Maggino T; Valente S; Pengo V; Marchesoni D
    Eur J Gynaecol Oncol; 1981; 2(3):127-8. PubMed ID: 7347682
    [No Abstract]   [Full Text] [Related]  

  • 39. Ciliated ovarian adenocarcinoma cells in ascitic fluid cytology: report of a case with immunocytochemical features.
    Kobayashi TK; Teraoka S; Tsujioka T; Yoshida Y
    Diagn Cytopathol; 1988; 4(3):234-8. PubMed ID: 2474417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Identification of fibrinogen or fibrin degradation products in the ascitic fluid].
    Kolodie L; Detante J; Rachail M
    Nouv Presse Med; 1978 Feb; 7(8):665. PubMed ID: 417295
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.